| Business Summary | | Becton,
Dickinson
and
Company
is
engaged
principally
in
the
manufacture
and
sale
of
supplies,
devices
and
systems
used
by
healthcare
professionals,
medical
research
institutions
and
the
general
public.
The
Company's
operations
consist
of
three
worldwide
business
segments:
Medical
Systems,
Biosciences,
and
Preanalytical
Solutions.
The
Medical
Systems
segment
produces
hypodermic
products,
specially
designed
devices
for
diabetes
care,
prefillable
drug
delivery
systems
and
infusion
therapy
products.
The
Biosciences
segment
provides
clinical
and
industrial
microbiology
products,
cellular
analysis
systems,
research
and
clinical
reagents
for
cellular
and
nucleic
acid
analysis,
cell
culture
labware,
and
growth
media,
hematology
instruments
and
other
diagnostic
systems,
including
immunodiagnostic
test
kits.
The
Preanalytical
Solutions
segment
provides
specimen
collection
products
and
services,
including
specimen
management
systems. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Becton,
Dickinson
and
Company
manufactures
and
sells
a
broad
line
of
supplies,
devices
and
systems
used
by
health
care
professionals,
medical
research
institutions
and
the
general
public.
For
the
nine
months
ended
6/30/01,
revenues
rose
2%
to
$2.76
billion.
Net
income
applicable
to
Common
fell
2%
to
$301.2
million.
Results
reflect
higher
sales
of
insulin
syringes
and
strong
sales
of
advanced
protection
devices,
offset
by
a
$3
million
loss
on
foreign
exchange
and
hedging
costs. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Clateo Castellini, 65 Chairman | $566K | -- | Edward Ludwig, 49 CEO,
Pres, | 993K | $51K | John Considine, 50 Exec.
VP, CFO | 508K | -- | Vincent Florenza, 47 Sr.
VP-Technology, Strategy and Devel. | 491K | 168K | William Kozy, 48 Sr.
VP- Operations | -- | -- | Dollar
amounts are as of 30-Sep-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|